Hormonal Research

HCG
Human Chorionic Gonadotropin

HCG is a glycoprotein hormone that acts as a structural and functional analogue of LH (luteinizing hormone) — binding the LH/HCG receptor on Leydig cells to drive testosterone production and on ovarian granulosa cells to trigger ovulation. It is FDA approved for multiple indications and has extensive clinical use in reproductive medicine.

LH AnalogueTestosteroneFertilityTesticular FunctionLeydig CellsGonadotropin

At a Glance

CAS Number

9002-61-3

Molecular Weight

~36,700 Da (glycoprotein)

Class

237 AA (alpha) + 145 AA (beta) glycoprotein

Published Studies

Extensive clinical

Stability

Requires refrigeration

Research Status

FDA approved (multiple indications)

Contents

Overview Mechanism Research Areas Protocols Comparison Safety FAQ

← Back to Research Library

Overview

HCG's beta subunit determines its LH-like activity. The two share a common alpha subunit but differ at the beta chain — HCG's extended beta C-terminal peptide (CTP) gives it a much longer half-life than LH (~24 hours vs ~1 hour), making it more practical for clinical and research protocols.

In male research contexts, HCG is used to maintain testicular function during TRT (preventing testicular atrophy) and to restore spermatogenesis. In female fertility research, it triggers the LH surge equivalent for oocyte maturation and ovulation induction.

"HCG is the LH surrogate with a 24-hour half-life — it provides the Leydig cell stimulation that LH would supply, but in a form practical enough for research and clinical use. In male research, it's the tool that keeps the testis functional."

Its cross-reactivity with TSH receptors at high concentrations is also studied — explaining the hyperthyroidism sometimes observed in gestational trophoblastic disease where HCG levels are extremely elevated.

Mechanism of Action

This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.

🔬

LH Receptor Agonism

Binds LH/HCG receptors on Leydig cells to stimulate testosterone synthesis — the direct LH analogue mechanism with 24-hour half-life.

🧬

Leydig Cell Stimulation

Drives intratesticular testosterone production — the mechanism used to maintain testicular volume and function during exogenous TRT.

🥚

Ovulation Triggering

In women, binds LH receptors on follicles to trigger oocyte maturation and ovulation — used in ART (assisted reproductive technology) protocols.

♻️

Spermatogenesis Support

FSH + HCG combination protocols restore spermatogenesis in hypogonadotropic hypogonadism — intratesticular testosterone is essential for sperm maturation.

Key Research Areas

Preclinical and clinical models have investigated this compound across a wide range of physiological contexts and tissue types.

Male hypogonadism and TRT adjunct — testicular volume maintenance and spermatogenesis preservation
IVF and ART — ovulation triggering (oocyte maturation induction)
Spermatogenesis restoration — in combination with FSH for hypogonadotropic hypogonadism
Undescended testes (cryptorchidism) — FDA-approved indication
Intratesticular testosterone studies — central role in male reproductive physiology
Comparison with kisspeptin as ovulation trigger — OHSS risk differential
HPG axis characterization — Leydig cell responsiveness testing

HCG's long half-life and direct LH receptor action make it the most practical tool for Leydig cell stimulation and ovulation triggering in both clinical and research contexts.

Compound Comparison

HCG vs kisspeptin for IVF triggering is one of the most active comparisons in reproductive medicine research — direct LH receptor activation vs physiological LH surge induction.

Aspect	HCG	LH (native)	Kisspeptin
Half-Life	~24 hours	~1 hour	~28 min (kisspeptin-10)
Primary Action	Direct LH receptor agonism	Direct LH receptor agonism	Triggers endogenous LH surge
FDA Status	Approved (multiple)	Not used as drug	Not approved
OHSS Risk (IVF)	High	High	Lower
Male Research Use	TRT adjunct, spermatogenesis	Reference only	HPG axis gating

Safety Profile in Research Studies

The following reflects findings from published preclinical and clinical safety assessments where available.

FDA approved across multiple indications — extensive human safety and efficacy data

Long half-life vs native LH — 24-hour vs 1-hour, enabling practical dosing

Preserves testicular function during TRT — the standard tool for maintaining intratesticular testosterone

OHSS risk in IVF — the sustained LH-like stimulus can cause ovarian hyperstimulation; kisspeptin being explored as safer alternative

Frequently Asked Questions

Why is HCG used alongside TRT?

Exogenous testosterone suppresses LH, removing the signal that drives intratesticular testosterone production. Without LH (or HCG), the testes shrink and sperm production stops. Adding HCG directly stimulates Leydig cells, maintaining intratesticular testosterone and preserving testicular volume.

Can HCG restore fertility after TRT?

Yes — HCG (often combined with FSH or clomiphene) is used to restart spermatogenesis in men who've experienced TRT-induced suppression. The protocol restimulates the Leydig cells and, with FSH support, can restore sperm production.

How does HCG differ from kisspeptin for IVF?

HCG directly activates LH receptors for an extended ~24-hour period — reliable but higher OHSS risk. Kisspeptin triggers the body's own LH surge, which is shorter and self-limiting — potentially lower OHSS risk with similar pregnancy rates. Both are in active clinical research.

Is there a long-acting HCG analogue?

Choriogonadotropin alfa (rhCG) is a recombinant form used in ART. Long-acting LH/HCG receptor agonists are being developed for less frequent dosing in hypogonadism research.

This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026